Brown Brothers Harriman & Co. Decreases Position in Kenvue Inc. (NYSE:KVUE)

Brown Brothers Harriman & Co. lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 317,046 shares of the company's stock after selling 80,543 shares during the period. Brown Brothers Harriman & Co.'s holdings in Kenvue were worth $6,769,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Grove Bank & Trust boosted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Kenvue during the fourth quarter worth approximately $29,000. SRS Capital Advisors Inc. boosted its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC boosted its stake in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Barclays raised their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Thursday, March 27th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and an average price target of $24.00.

Remove Ads

Kenvue Trading Down 0.6 %

Kenvue stock traded down $0.14 during midday trading on Tuesday, reaching $23.85. 11,113,788 shares of the stock traded hands, compared to its average volume of 16,722,053. The firm has a market cap of $45.57 billion, a PE ratio of 44.99, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day simple moving average of $22.38 and a two-hundred day simple moving average of $22.46.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.